BlackRock’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.78B | Sell |
|
|||||
|
2025
Q2 | $1.63B | Sell |
|
|||||
|
2025
Q1 | $1.62B | Sell |
|
|||||
|
2024
Q4 | $2.02B | Buy |
|
|||||
|
2024
Q3 | $1.64B | Buy |
|
|||||
|
2024
Q2 | $1.95B | Buy |
|
|||||
|
2024
Q1 | $1.9B | Buy |
|
|||||
|
2023
Q4 | $1.8B | Buy |
|
|||||
|
2023
Q3 | $1.5B | Sell |
|
|||||
|
2023
Q2 | $1.27B | Buy |
|
|||||
|
2023
Q1 | $1.36B | Buy |
|
|||||
|
2022
Q4 | $1.51B | Buy |
|
|||||
|
2022
Q3 | $1.28B | Buy |
|
|||||
|
2022
Q2 | $1.16B | Buy |
|
|||||
|
2022
Q1 | $1.09B | Buy |
|
|||||
|
2021
Q4 | $977M | Buy |
|
|||||
|
2021
Q3 | $980M | Buy |
|
|||||
|
2021
Q2 | $987M | Sell |
|
|||||
|
2021
Q1 | $1.07B | Buy |
|
|||||
|
2020
Q4 | $671M | Buy |
|
|||||
|
2020
Q3 | $655M | Sell |
|
|||||
|
2020
Q2 | $916M | Buy |
|
|||||
|
2020
Q1 | $602M | Buy |
|
|||||
|
2019
Q4 | $709M | Buy |
|
|||||
|
2019
Q3 | $535M | Buy |
|
|||||
|
2019
Q2 | $478M | Buy |
|
|||||
|
2019
Q1 | $484M | Buy |
|
|||||
|
2018
Q4 | $356M | Sell |
|
|||||
|
2018
Q3 | $627M | Buy |
|
|||||
|
2018
Q2 | $499M | Buy |
|
|||||
|
2018
Q1 | $407M | Buy |
|
|||||
|
2017
Q4 | $371M | Sell |
|
|||||
|
2017
Q3 | $298M | Buy |
|
|||||
|
2017
Q2 | $221M | Sell |
|
|||||
|
2017
Q1 | $218M | Buy |
|
|||||
|
2016
Q4 | $1.36M | Sell |
|
|||||
|
2016
Q3 | $3.89M | Buy |
|
|||||
|
2016
Q2 | $3.28M | Buy |
|
|||||
|
2016
Q1 | $2.53M | Sell |
|
|||||
|
2015
Q4 | $4.15M | Buy |
|
|||||
|
2015
Q3 | $1.86M | Sell |
|
|||||
|
2015
Q2 | $2.59M | Sell |
|
|||||
|
2015
Q1 | $2.21M | Sell |
|
|||||
|
2014
Q4 | $1.65M | Sell |
|
|||||
|
2014
Q3 | $1.76M | Sell |
|
|||||
|
2014
Q2 | $1.8M | Buy |
|
|||||
|
2014
Q1 | $1.89M | Buy |
|
|||||
|
2013
Q4 | $21K | Hold |
|
|||||
|
2013
Q3 | $25K | Hold |
|
|||||
|
2013
Q2 | $29K | Buy |
|